Aarti Drugs Limited (AARTIDRUGS) - Net Assets
Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has net assets worth Rs14.69 Billion INR (≈ $158.82 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs26.12 Billion ≈ $282.51 Million USD) and total liabilities (Rs11.44 Billion ≈ $123.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aarti Drugs Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs14.69 Billion |
| % of Total Assets | 56.22% |
| Annual Growth Rate | 14.71% |
| 5-Year Change | 49.92% |
| 10-Year Change | 283.14% |
| Growth Volatility | 8.18 |
Aarti Drugs Limited - Net Assets Trend (2006–2025)
This chart illustrates how Aarti Drugs Limited's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Aarti Drugs Limited for the complete picture of this company's asset base.
Annual Net Assets for Aarti Drugs Limited (2006–2025)
The table below shows the annual net assets of Aarti Drugs Limited from 2006 to 2025. For live valuation and market cap data, see market cap of Aarti Drugs Limited.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs13.69 Billion ≈ $148.09 Million |
+6.82% |
| 2024-03-31 | Rs12.82 Billion ≈ $138.64 Million |
+7.49% |
| 2023-03-31 | Rs11.93 Billion ≈ $128.98 Million |
+15.09% |
| 2022-03-31 | Rs10.36 Billion ≈ $112.07 Million |
+13.45% |
| 2021-03-31 | Rs9.13 Billion ≈ $98.78 Million |
+39.99% |
| 2020-03-31 | Rs6.52 Billion ≈ $70.56 Million |
+20.06% |
| 2019-03-31 | Rs5.43 Billion ≈ $58.77 Million |
+19.33% |
| 2018-03-31 | Rs4.55 Billion ≈ $49.25 Million |
+10.89% |
| 2017-03-31 | Rs4.11 Billion ≈ $44.42 Million |
+14.92% |
| 2016-03-31 | Rs3.57 Billion ≈ $38.65 Million |
+15.98% |
| 2015-03-31 | Rs3.08 Billion ≈ $33.33 Million |
+22.82% |
| 2014-03-31 | Rs2.51 Billion ≈ $27.13 Million |
+20.85% |
| 2013-03-31 | Rs2.08 Billion ≈ $22.45 Million |
+17.64% |
| 2012-03-31 | Rs1.76 Billion ≈ $19.09 Million |
+8.16% |
| 2011-03-31 | Rs1.63 Billion ≈ $17.65 Million |
+11.41% |
| 2010-03-31 | Rs1.46 Billion ≈ $15.84 Million |
+18.63% |
| 2009-03-31 | Rs1.23 Billion ≈ $13.35 Million |
+10.68% |
| 2008-03-31 | Rs1.12 Billion ≈ $12.06 Million |
+11.40% |
| 2007-03-31 | Rs1.00 Billion ≈ $10.83 Million |
-0.85% |
| 2006-03-31 | Rs1.01 Billion ≈ $10.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aarti Drugs Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1240265800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs12.40 Billion | 90.60% |
| Common Stock | Rs912.70 Million | 6.67% |
| Other Comprehensive Income | Rs374.63 Million | 2.74% |
| Other Components | Rs15.00K | 0.00% |
| Total Equity | Rs13.69 Billion | 100.00% |
Aarti Drugs Limited Competitors by Market Cap
The table below lists competitors of Aarti Drugs Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DB Financial Investment Co Ltd
KO:016610
|
$371.48 Million |
|
Bhagiradha Chemicals & Industries Limited
NSE:BHAGCHEM
|
$371.49 Million |
|
West Bancorporation
NASDAQ:WTBA
|
$371.51 Million |
|
Bohai Water Industry Co Ltd
SHE:000605
|
$371.56 Million |
|
Jiangsu Yuxing Film Tech
SHE:300305
|
$371.35 Million |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
$371.25 Million |
|
Shivalik Bimetal Controls Limited
NSE:SBCL
|
$370.98 Million |
|
Thessaloniki Port Authority SA
AT:OLTH
|
$370.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aarti Drugs Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,815,485,000 to 13,690,000,000, a change of 874,515,000 (6.8%).
- Net income of 1,681,600,000 contributed positively to equity growth.
- Dividend payments of 90,600,000 reduced retained earnings.
- Share repurchases of 731,700,000 reduced equity.
- Other comprehensive income increased equity by 30,975,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs1.68 Billion | +12.28% |
| Dividends Paid | Rs90.60 Million | -0.66% |
| Share Repurchases | Rs731.70 Million | -5.34% |
| Other Comprehensive Income | Rs30.98 Million | +0.23% |
| Other Changes | Rs-15.76 Million | -0.12% |
| Total Change | Rs- | 6.82% |
Book Value vs Market Value Analysis
This analysis compares Aarti Drugs Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.52x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 51.24x to 2.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs7.34 | Rs376.30 | x |
| 2007-03-31 | Rs10.69 | Rs376.30 | x |
| 2008-03-31 | Rs11.91 | Rs376.30 | x |
| 2009-03-31 | Rs13.18 | Rs376.30 | x |
| 2010-03-31 | Rs14.97 | Rs376.30 | x |
| 2011-03-31 | Rs16.84 | Rs376.30 | x |
| 2012-03-31 | Rs18.22 | Rs376.30 | x |
| 2013-03-31 | Rs21.43 | Rs376.30 | x |
| 2014-03-31 | Rs25.90 | Rs376.30 | x |
| 2015-03-31 | Rs31.81 | Rs376.30 | x |
| 2016-03-31 | Rs36.90 | Rs376.30 | x |
| 2017-03-31 | Rs43.04 | Rs376.30 | x |
| 2018-03-31 | Rs48.28 | Rs376.30 | x |
| 2019-03-31 | Rs57.61 | Rs376.30 | x |
| 2020-03-31 | Rs70.01 | Rs376.30 | x |
| 2021-03-31 | Rs98.01 | Rs376.30 | x |
| 2022-03-31 | Rs111.92 | Rs376.30 | x |
| 2023-03-31 | Rs128.77 | Rs376.30 | x |
| 2024-03-31 | Rs139.40 | Rs376.30 | x |
| 2025-03-31 | Rs149.39 | Rs376.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aarti Drugs Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.28%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.04%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 1.88x
- Recent ROE (12.28%) is below the historical average (17.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 15.24% | 5.29% | 0.69x | 4.18x | Rs46.11 Million |
| 2007 | 13.75% | 4.76% | 0.79x | 3.66x | Rs37.56 Million |
| 2008 | 12.32% | 4.40% | 0.75x | 3.74x | Rs25.84 Million |
| 2009 | 12.93% | 4.18% | 0.95x | 3.27x | Rs36.21 Million |
| 2010 | 19.94% | 5.90% | 1.14x | 2.96x | Rs140.72 Million |
| 2011 | 14.53% | 4.73% | 0.96x | 3.21x | Rs73.97 Million |
| 2012 | 12.24% | 3.28% | 1.08x | 3.47x | Rs39.56 Million |
| 2013 | 21.79% | 5.48% | 1.15x | 3.47x | Rs244.78 Million |
| 2014 | 24.60% | 6.36% | 1.14x | 3.39x | Rs366.22 Million |
| 2015 | 25.07% | 7.06% | 1.09x | 3.25x | Rs464.39 Million |
| 2016 | 19.23% | 6.06% | 1.03x | 3.08x | Rs329.85 Million |
| 2017 | 19.62% | 6.74% | 1.02x | 2.87x | Rs394.91 Million |
| 2018 | 18.07% | 6.62% | 0.90x | 3.05x | Rs367.64 Million |
| 2019 | 16.52% | 5.75% | 1.07x | 2.69x | Rs354.07 Million |
| 2020 | 21.67% | 7.83% | 1.15x | 2.42x | Rs761.52 Million |
| 2021 | 30.70% | 13.01% | 1.22x | 1.93x | Rs1.89 Billion |
| 2022 | 19.78% | 8.24% | 1.13x | 2.13x | Rs1.01 Billion |
| 2023 | 13.95% | 6.12% | 1.12x | 2.03x | Rs470.67 Million |
| 2024 | 13.38% | 6.78% | 1.04x | 1.90x | Rs432.63 Million |
| 2025 | 12.28% | 7.04% | 0.93x | 1.88x | Rs312.60 Million |
Industry Comparison
This section compares Aarti Drugs Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $25,623,128,624
- Average return on equity (ROE) among peers: 7.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aarti Drugs Limited (AARTIDRUGS) | Rs14.69 Billion | 15.24% | 0.78x | $371.43 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more